Display options
Cite
Evans JP, Winiarski BK, Sutton PA, et al. Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer. Oncotarget. 2019;10(6):685doi: 10.18632/oncotarget.26625.
Evans, J. P., Winiarski, B. K., Sutton, P. A., Jones, R. P., Ressel, L., Duckworth, C. A., Pritchard, D. M., Lin, Z. X., Fretwell, V. L., Tweedle, E. M., Costello, E., Goldring, C. E., Copple, I. M., Park, B. K., Palmer, D. H., & Kitteringham, N. R. (2019). Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer. Oncotarget, 10(6), 685. https://doi.org/10.18632/oncotarget.26625
Evans, Jonathan P, et al. "Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer." Oncotarget vol. 10,6 (2019): 685. doi: https://doi.org/10.18632/oncotarget.26625
Evans JP, Winiarski BK, Sutton PA, Jones RP, Ressel L, Duckworth CA, Pritchard DM, Lin ZX, Fretwell VL, Tweedle EM, Costello E, Goldring CE, Copple IM, Park BK, Palmer DH, Kitteringham NR. Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer. Oncotarget. 2019 Jan 18;10(6):685. doi: 10.18632/oncotarget.26625. eCollection 2019 Jan 18. PMID: 30774766; PMCID: PMC6363008.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2019 Jan 18;10(6):685. doi: 10.18632/oncotarget.26625. eCollection 2019 Jan 18.

Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer.

Oncotarget

Jonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, Robert P Jones, Lorenzo Ressel, Carrie A Duckworth, D Mark Pritchard, Zhi-Xiu Lin, Vicky L Fretwell, Elizabeth M Tweedle, Eithne Costello, Christopher E Goldring, Ian M Copple, B Kevin Park, Daniel H Palmer, Neil R Kitteringham

Affiliations

  1. Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
  2. MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
  3. Department of Veterinary Pathology, Institute of Veterinary Science, University of Liverpool, Liverpool, United Kingdom.
  4. Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
  5. School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.
  6. Clatterbridge Cancer Centre, Liverpool, United Kingdom.

PMID: 30774766 PMCID: PMC6363008 DOI: 10.18632/oncotarget.26625

Abstract

[This corrects the article DOI: 10.18632/oncotarget.25497.].

Publication Types